

OPEN ACCESS MACEDONIAN  
JOURNAL OF MEDICAL SCIENCES

oa  
mjms

BB Clinical  
Sciences



ISSN 1857-9664 (print) / ISSN 1857-9672 (online) / DOI: 10.5937/mjms

# Open Access Macedonian Journal of Medical Sciences

About ▾ Announcements Current ▾ Archives NCBI ▾ EU ▾ Scopus ▾ CABI ▾  
Indexation ▾ Membership ▾ No Publication Fee: ▾

[Home](#) / [Editorial Team](#)

## Editorial Team

### Journal Manager

Dr. Eli Djulejic, Open Access Macedonian Journal of Medical Sciences, Belgrade, Serbia

### Editor-in-Chief

[Prof. Dr. Mirko Zhivko Spiroski](#), Scientific Foundation SPIROSKI, Rajko Zhinzifov No 48, 1000 Skopje, Republic of Macedonia

### Section Editors (Deputy Editors-in-Chief)

Dimitrov Borislav D, MD. Academic Unit of Primary Care and Population Sciences Faculty of Medicine University of Southampton South Academic Block (Level C) Southampton General Hospital Southampton SO166YD England, UK

Mukaetova-Ladinska Elizabeta, MD, PhD, MRCPsych. Old Age Psychiatry, Newcastle University, United Kingdom

Branislav FilipoviÄ, MD, PhD. University of Belgrade, Faculty of Medicine, Institute of Anatomy â€œNiko Miljanicâ€

Address: 4/2 Dr Subotica Starijeg, Belgrade, Serbia

Spiroski Igor, MD. University Clinic of Cardiology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia

Stoleski Sasho, MD, PhD. Institute for Occupational Health of Republic of Macedonia - Skopje, WHO Collaborating Center, GA2LEN Collaborating Center, II Makedonska brigada 43, 1000 Skopje, Republic of Macedonia

Hristomanova-Mitkovska Slavica, MD, MSc. Institute for Human Genetics of the Faculty of Medicine in GÄttingen, Germany

Bogoeva Ksenija, MD, PhD. PHO Prof Bogoev, Skopje, Republic of Macedonia

Stojanovski, Sinisa, MD, PhD.

### **Layout Editor and Electronic Publishing**

MSc, Eng Ivo Spiroski, ID Design 2012, Skopje, Republic of Macedonia

### **Copyeditor**

Sinjore, India

### **Evidence Based Medicine**

Prof. Dr. Katarina Stavric, Children Hospital Skopje, Macedonia, Vodnjanska 17, University "Ss Cyril and Methodius", Skopje, Republic of Macedonia

### **Editorial Board**

DDS, MS, PhD, Associate Professor Nikola Angelov, Director of the Pre-Doctoral Periodontics Clinic, Loma Linda University School of Dentistry, Department of Periodontics. Loma Linda, CA, 92350, United States

Assist. Prof. Dr. Ramush Bejiqi, University Clinical Centre of Kosovo, Paediatric Clinic, Albania

Prof. Semra Āevaljuga, Department of Epidemiology and Biostatistics, Faculty of Medicine, Sarajevo, Bosnia and Herzegovina

MD Pei-Yi Chu, Diagnostic and research pathologist, Department of Surgical Pathology, Changhua Christian Hospital, Taiwan. Address: 135 Nan-Shiao Street, Changhua 500-06,, Taiwan, Province of China

MD, PhD Ivo Donkov, Staff Urologist, Lincoln County Hospital, United Kingdom

Prof. Dr. Aleksandar Dimovski, Institute of Pharmaceutical Chemistry, Faculty of Pharmacy, University "Ss Kiril and Metodij", Skopje, Republic of Macedonia

MD, PhD Andrew J. Dwork, Departments of Pathology and Cell Biology and Psychiatry, College of Physicians and Surgeons of Columbia University; Division of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, Unit 62, 722 West 168th Street, New York, NY 10032, United States

Adriana Galan, Department of Health Programmes and Health Promotion, Institute of Public Health, Bucharest, Romania

Prof. Tania Santos Giani, Estacio de Sa University, in Health Sciences, Brazil

PhD Iva Ivanovska, Harvard Medical School, Department of Genetics, 77 Avenue Louis Pasteur, NRB room 239, Boston, MA 02115, United States

MD, PhD Jerzy JabÅecki, Associate Professor, Division of General Surgery St. Jadwiga of Silesia Hospital, Trzebnica; Head, Subdepartment of Hand Surgery an Replantation St Jadwiga of Silesia Hospital, Trzebnica; Professor, Department of Public Health, State Higher Professional Medical School, Opole, Poland. 55-100 Trzebnica, ul. Prusicka 53, Poland

MD Mehrdad Jalalian Hosseini, Khorasan-e Razavi Blood Center, Mashhad, Iran, Islamic Republic of

PhD Radka Kaneva, Department of Medical Chemistry and Biochemistry, Medical University - Sofia, Bulgaria

Prof. Dr. Kostandina Leonida Korneti-Pekevka, Ss Cyril and Methodius University of Skopje, Faculty of Medicine, Skopje, Republic of Macedonia

MD, PhD Branko Malenica, Department of Immunology, Clinical Hospital Center Zagreb, Zagreb University School of Medicine, Zagreb, Croatia

Prof. Dr. Elida Mitevka, Institute of Histology and Embriology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia

MD, PhD Marija Mostarica-StojkoviÅž, Institute of Microbiology and Immunology, University of Belgrade School of Medicine, Belgrade, Serbia

PhD Vesna Nikolova-Krsteovski, Harvard Institutes of Medicine, HIM-201, 4 Blackfan Circle, Boston, MA, 02134, United States

Prof. Dr. Nikola Panovski, Institute of Microbiology and Parasitology, Faculty of Medicine, Skopje, Republic of Macedonia

MD, BIDMC Iva Petkovska, Beth Israel Deaconess Medical Center Radiology W CC - 3 330 Brookline Ave. Boston, MA 02215, United States

Prof. Dr. Gordana Petrusevska, Institute of Pathology, Medical Faculty, University of "Ss. Cyril and Methodius" Skopje, Republic of Macedonia

Prof. Enver Roshi, Dean of Faculty of Public Health, Medical University of Tirane, Chief of Epidemiological Observatory, National Institute of Public Health. Address: Rruga e Dibrës, Str. 371, Tirana, Albania

MD, PhD Gorazd B. Rosoklija, Professor at Columbia University and member of the Macedonian Academy of Sciences and Arts, United States

Prof. Dr. Aleksandar Sikole, University Clinic for Nephrology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia

MD, FESC Gianfranco Sinagra, Department of Cardiology, "Ospedali Riuniti" and University of Trieste, Ospedale Cattinara " Strada di Fiume, 447, 34149 " Trieste, Italy

MD, PhD Rumen Stefanov, Information Centre for Rare Diseases and Orphan Drugs (ICRDOD), Bulgaria; Department of Social Medicine, Medical University of Plovdiv, Bulgaria

Prof. Dr. Vesna Velikj Stefanovska, Department of Epidemiology and Biostatistics with Medical Informatics, Medical Faculty, UKIM, Skopje, Republic of Macedonia

MD, MBA Milenko Tanasijevic, Director, Clinical Laboratories Division and Clinical Program Development, Pathology Department, Brigham and Women's Hospital, Dana Farber Cancer Institute, Associate Professor of Pathology, Harvard Medical School, United States

PhD Mirko Trajkovski, ETH Zürich, Wolfgang-Pauli-Str. 16/HPT D57, 8093 Zürich-CH, Switzerland

MD, FRCPC Kiril Trpkov, Associate Professor, University of Calgary, Department of Pathology and Laboratory Medicine, Calgary Laboratory Services. 7007 14 st, Calgary SW, Canada

MD, PhD Igor Tulevski, Department of Cardiology, Academic Medical Center, Amsterdam, 1100 DD, T 020 707 2930; F 020 707 2931, Netherlands

PhD Zoran Zdravkovski, Institute of Chemistry, Faculty of Natural Sciences and Mathematics, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia

## Past Members of Editorial Team

Prof. Dr Doncho Donev, Institute of Social Medicine, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia

Prof. Dr Olivera Stojceva Taneva, University Clinic of Nephrology, Republic of Macedonia

Prof. Dr Petar Miloshevski, from 2008-2014, Institute of Preclinical and Clinical Pharmacology with Toxicology, Faculty of Medicine, Skopje, Republic of Macedonia

Prof. Dr Sonja Topuzovska, Institute of Medical and Experimental Biochemistry, Faculty of Medicine, Skopje, Republic of Macedonia

## Open Journal Systems

## Information

[For Readers](#)

[For Authors](#)

[For Librarians](#)

[Make a Submission](#)

## Browse

### Categories

[A - Basic Sciences](#)

[B - Clinical Sciences](#)

[C - Case Reports](#)

[D - Dental Sciences](#)

[E - Public Health](#)

[F - Review Articles](#)

[T - Thematic Issues](#)

T1 - Thematic Issue "Coronavirus Disease (COVID-19)"

T2 - Thematic Issue "Public Health and Nutrition Sciences in the Current Millennial Era"

T3 - Thematic Issue "Neuroscience, Neurology, Psychiatry and General Medicine"

## Current Issue

ATCM 1.0

FES 2.0

RSS 1.0

### Published by



### About us

#### [About the Journal](#)

Editorial Team  
Author Fees  
Online Payments  
Bibliographic Information  
Journal History

### Information

[For readers](#)  
[For authors](#)  
[For librarians](#)  
[For Reviewers](#)  
Transparency

### Contact

Publisher  
Co  
publisher  
Registration  
Contact  
Privacy  
statement

Platform &  
workflow by  
**OJS / PKP**

1. [Home /](#)
2. [Archives /](#)
3. Vol. 8 No. B (2020): B - Clinical Sciences

## Vol. 8 No. B (2020): B - Clinical Sciences



Published: 2020-01-02

Gastroenterohepatology

- **Clinical outcomes of non-variceal upper gastrointestinal bleeding and its relation to aspirin and anticoagulants.**

Hend Radwan, Ehab Elsayed , Hesham Alshabrawi (Author)

11-19

○ [PDF](#)

- **Nonalcoholic Fatty Liver Disease and the Risk of Atrial Fibrillation**

Mahmoud A. Abou Omar, Ahmed Alaarag, Sherief Abd-Elsalam, Mohamed El-Abgeegy, Rehab Ahmed, Ahmed Abdelhaleem Mohamed, Mahmoud Khalil, Yousry Esam-Eldin Abo-Amer, Mahmoud Elkadeem, Mohamed Yousef (Author)

530-535

○ [PDF](#)

Nephrology

- **Drug-induced Nephropathy and Molecular Patterns of Oxidative Stress**

Valentina Lee, Ryszhan Bakirova, Larissa Muravlyova, Zhanara Turkhanova, Anar Rakhmetova (Author)

205-209

○ [PDF](#)

- **Non-invasive Hemodynamic Monitoring of Fluid Resuscitation in Cirrhotic Patients with Acute Kidney Injury**

Samir El Hadidy, Ahmed Albadry, Waheed Radwan, Amna Metwaly, Khaled Farouk (Author)

319-323

○ [PDF](#)

- **The Role of Serum Neutrophil Gelatinase-associated Lipocalin in the Early Diagnosis of Nephropathy in Patients with Acute Alcohol Poisoning**

L. Demidchik, D. Klyuyev , L. Muravlyova, V. Molotov-Luchanskiy , R. Bakirova (Author)

548-552

○ [PDF](#)

- **Blood Pressure and Blood Pressure Deficits as Predictors of Acute Kidney Injury in Vasopressor Dependent Patients Post Cardiovascular Surgery**

Ahmed Farghaly, AbdelRaof Fahmy, Mohamed Ameen, Khaled M. Taema, Gamal Hamed (Author)

542-547

○ [PDF](#)

Cardiology



- **Brain Natriuretic Peptide is a Predictor of Cardiac Thrombus in Critically Ill Acute Ischemic Stroke Patients**  
Hossam A. Mowafy, Hossam El Sherif, Khaled A. Wahab, Nora I. Abbas, Gihan El Hilaly, Doaa A. Eelgohary (Author)  
119-124
- [PDF](#)
- **Segmental Versus Circumferential Ablation of Pulmonary Veins in Patients with Paroxysmal Atrial Fibrillation**  
Ahmed Moustafa Wedn, Ahmed Eldamaty, Moataz Elhalag, Rania Elsherif, Hesham Alaasr (Author)  
85-98
- [PDF](#)
- **The Association between Cyanotic and Acyanotic Congenital Heart Disease with Nutritional Status**  
Putri Amelia, Rizky Adriansyah, Bastian Lubis, Muhammad Akil (Author)  
245-248
- [PDF](#)
- **Alcohol Use Disorder is Associated with an Increased Risk for Respiratory Failure among Patients with Takotsubo Cardiomyopathy**  
Temidayo Abe, Valery Effoe, Dolphurs Hayes, Obiora Egbuche, Huynh Ky, Taiwo Ajose, Adebanjo Olowu (Author)  
268-272
- [PDF](#)
- **Novel CHA2DS2-VASc-HSF is Superior to CHADS2 and CHA2DS2-VASc Score to Predict the Risk of Severe Coronary Artery Disease**  
Andrianto Andrianto, Benny Jovie, Makhyan Jibril Al Farabi, Parama Gandhi, Khubay Alvia Shonafi, Rofida Lathifah (Author)  
451-456
- [PDF](#)
- **Smart Touch Radiofrequency Catheter Ablation versus Cryoballoon Ablation of Pulmonary Veins in Patients with Paroxysmal Atrial Fibrillation**  
Walid Shehata Hassan, Sherief Hamed Zaky, Khaled Hussein Mohamed, Moataz Mohammed Ibrahim (Author)  
563-568
- [PDF](#)
- Pulmonology
- **Analysis of Liver Function on Leprosy Patient with Multidrug Therapy in Haji Adam Malik General Hospital Medan from January until December 2017**  
Mila Darmi, Ramona Dumasari Lubis (Author)  
58-61
- [PDF](#)
- **The Efficacy and Prevalence of Montelukast Therapy in Cough-Variant Asthma Patients in Al-Kindy Teaching Hospital**  
Saba Jasim Hamdan (Author)  
156-159
- [PDF](#)
- **The Impact of Short-term Combination of Limb Training and Pursed-lip Breathing in Chronic Obstructive Pulmonary Disease**  
Amira Permatasari Tarigan, Fannie Rizki Ananda, Pandiaman Pandia, Trisno Susilo, Maryaningsih Maryaningsih, Anggriani Anggriani (Author)  
479-483
- [PDF](#)

## Neurology

- **Optic Nerve Sheath Diameter Cutoff Point for Detection of Increased Intracranial Pressure in the Emergency Department**  
Wanatchaporn Ussahgij, Wipada Toonpirom, Waranon Munkong, Kamonwon Lenghong, Korakot Apiratwarakul (Author)  
62-65
  - [PDF](#)
- **Functional Outcome Following Synthetic Vertebral Body Implantation in the Management of Spinal Disorders**  
Moneer K. Faraj , Bassam Mahmood Flamerz Â Arkawazi, Hazim Moojid Abbas, Zaid Al-Attar (Author)  
76-80
  - [PDF](#)
- **The Effect of High- and Low-Frequency Repetitive Transcranial Magnetic Stimulation Therapy on Serum Brain-Derived Neurotropic Factor Level and Motor Ability in Ischemic Stroke Patients: A Single-Center Study**  
Andi Kurnia Bintang, Muhammad Akbar , Muhammad Yunus Amran, Nurussyariah Hammado (Author)  
198-204
  - [PDF](#)
- **Diagnosis Performance of Cerebral Venous Thrombosis with Magnetic Resonance Imaging and Magnetic Resonance Venography in Zahedan (Southeast of Iran): A Series of 57 Patients**  
Sharareh Sanei Sistani, Ali Khajeh, Hamed Amirifard, Mahdi Mohammadi, Hajar Derakhshandi, Bahareh Heshmat Ghahderijani (Author)  
423-428
  - [PDF](#)
- **The Difference of Brainstem Auditory Evoked Potential Latency in Diabetic Patient with Good and Poor Glycemic Control**  
D. P. G. Purwa Samatra, Grace Meliana, I. G. N. Purna Putra, I Putu Eka Widyadharma (Author)  
457-462
  - [PDF](#)
- **Blue Light Exposure Improving Cognitive Function by Increasing Serum Orexin Level in Shift Working Nurse at Sanglah Central Hospital Denpasar**  
Anak Agung Ayu Putri Laksmidewi, Yuliantry Indah Lestari, Ni Putu Ayu Putri Mahadewi, I. Made Oka Adnyana, Anak Agung Bagus Ngurah Nuartha (Author)  
446-450
  - [PDF](#)
- **Exploring the Relationship between Body Mass Index and Anxiety Status Among Ahlia University Students**  
Sayed Tantawy, Nada Ikram Karamat, Rana Sulaiman Al Gannas, Sara Abdulrahman Khadem, Dalia M. Kamel (Author)  
20-25
  - [PDF](#)
- **Biomarkers of Oxidative Stress in Major Depressive Disorder**  
Rania A. Hamed, Heba A. Elmalt, Abeer A. Salama, Sarah Y. Abozaid, Amani S. Ahmed (Author)  
501-506
  - [PDF](#)
- **Psychophysiological Status and Life Quality in Individuals with Metabolic Syndrome Living in Central Kazakhstan**  
Berik Koichubekov, Marina Sorokina, Ilya Korshukov, Riszhan Bakirova, Emur Bekov, Nazgul Omarbekova (Author)  
463-469

Platform &  
workflow by  
OJS / PKP



# Novel CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF is Superior to CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc Score to Predict the Risk of Severe Coronary Artery Disease

Andrianto Andrianto<sup>1\*</sup>, Benny Jovie<sup>2</sup>, Makhyan Jibril Al-Farabi<sup>1,3</sup>, Parama Gandhi<sup>1,2</sup>, Khubay Alvia Shonafi<sup>1</sup>, Rofda Lathifah<sup>4</sup>

<sup>1</sup>Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga – Dr Soetomo Academic General Hospital, Surabaya, Indonesia; <sup>2</sup>Department of Cardiology and Vascular Medicine, Dr Ramelan Navy Hospital, Surabaya, Indonesia; <sup>3</sup>School of Healthcare Management, University College London, Gower St, Bloomsbury, London, United Kingdom; <sup>4</sup>Department of Health Policy and Administration, Faculty of Public Health, Universitas Airlangga, Surabaya, Indonesia

## Abstract

**Edited by:** Ksenija Bogoeva, Kostovska  
**Citation:** Andrianto A, Jovie B, Al-Farabi MJ, Gandhi P, Shonafi KA, Lathifah R. Novel CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF is Superior to CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc Score to Predict the Risk of Severe Coronary Artery Disease. Open Access Maced J Med Sci. 2020 Apr 12; 8(B):451-456. https://doi.org/10.3889/oamjms.2020.3393  
**Keywords:** Atherosclerosis; Coronary occlusion; Gensini score; Risk stratification

\*Correspondence: Andrianto Andrianto, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo Academic General Hospital, Surabaya, Indonesia. Tel.: +62-31-502-0251 (A). E-mail: andrianto@fk.unair.ac.id

Received: 20-Jul-2019  
Revised: 07-Jan-2020  
Accepted: 27-Feb-2020  
Copyright: © 2020 Andrianto Andrianto, Benny Jovie, Makhyan Jibril Al-Farabi, Parama Gandhi, Khubay Alvia Shonafi, Rofda Lathifah  
**Funding:** This research did not receive any financial support  
**Competing Interests:** The authors have declared that no competing interests exist  
**Open Access:** This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)

**BACKGROUND:** Various risk scoring methods are available to predict the severity of coronary artery disease (CAD). However, the majority of them are complex and require advanced technologies, thus limiting its usage in primary care settings. CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF is a novel risk scoring which we develop from CHA<sub>2</sub>DS<sub>2</sub>-VASc score.

**AIM:** We hypothesize that CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF is predictive for the risk of severe CAD, and we compare its validity with previously established CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc score.

**MATERIALS AND METHODS:** A total of 210 patients who underwent elective coronary angiography were enrolled in our study. Anthropometric, laboratory, angiographic findings, and patient history were obtained from medical records and used to calculate CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF score. Severe CAD defined as coronary artery occlusion with the Gensini score of  $\geq 20$ . Statistical analyses were done using SPSS 25.0 and MedCalc 18.2.1.

**RESULTS:** This research showed that the patient with severe CAD has significantly higher CHADS<sub>2</sub>, CHA<sub>2</sub>DS<sub>2</sub>-VASc, and CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF score compared to normal and mild CAD ( $p < 0.001$ ). CHADS<sub>2</sub>, CHA<sub>2</sub>DS<sub>2</sub>-VASc, and CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF correlated significantly with the CAD severity ( $r = 0.315$ ,  $p \leq 0.001$ ;  $r = 0.395$ ,  $p \leq 0.001$ ;  $r = 0.612$ ,  $p \leq 0.001$ , respectively). CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF may predict the risk of severe CAD independent from other variables (odds ratio = 2.540; 95% confidence interval = 1.794–3.595;  $p = 0.002$ ) with the cutoff value of  $\geq 2.5$  (sensitivity = 81.4% and specificity = 68.1%). Pairwise comparison of receiver operating characteristic curves showed that CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF was superior to predict severe CAD.

**CONCLUSIONS:** CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF scores may predict the risk of severe CAD better than CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc score. This score may easily be used in primary care physicians to predict the risk of severe CAD and provide an early referral to the cardiologist.

## Introduction

Coronary artery disease (CAD) remained the top cause of mortality and morbidity for a person aged 35 and over worldwide [1], [2]. Failure to detect CAD and provide early treatment may cause CAD treatment to become a more expensive and higher mortality rate [2]. It is estimated that around one-third of the middle age's population in the USA will suffer from CAD manifestation [3]. In Indonesia, the Indonesian Ministry of Health also showed that CAD is the leading cause of morbidity, which is responsible for 12.9% of death [4].

Determining the best risk factor assessment for CAD is extremely important for early prevention and treatment. The screening for CAD using angiography is easily available in developed countries with short waiting lists. However, in developing countries, the awareness and accessibility of cardiovascular disease screening are still low [5]. To obtain cost-effective prevention and treatment of CAD at the patient level, stratification of the

cardiovascular risk using a simple method is extremely important. Cardiovascular risk screening will have a relevant implication for decision making in early referral and healthcare resource allocation [6].

At present, CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores have been established as clinical predictors for cardiac thromboembolism and indication of antithrombotic therapy [7]. Both CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc component has similarities with the risk factors of CAD development [8]. The components within the CHADS<sub>2</sub> score also had been proven in large cohort studies to be associated with CAD in with ischemic stroke patients [9], while CHA<sub>2</sub>DS<sub>2</sub>-VASc is the refinement of CHADS<sub>2</sub> score, which has been proven to outperform its predecessor in the various patient group, including AF patient who received elective electrical cardioversion [10]. This suggests CHA<sub>2</sub>DS<sub>2</sub>-VASc score may predict the risk for both cerebrovascular and cardiovascular diseases. However, these scores did not include the major risk factors of CAD such as smoking, hyperlipidemia, and family histories. Hence, this

research aims to improve the validity of the CHA<sub>2</sub>DS<sub>2</sub>-VASc score by including new major risk factor of CAD which are hyperlipidemia (H), smoking (S), and family history of CAD (F) and compare it with the previous CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc score to predict severe CAD in the patients.

## Materials and Methods

### Study design

This cross-sectional study involves 210 consecutive patients who underwent coronary angiography in the Cardiology Department of Ramelan Navy Hospital Surabaya during 1 year period between January-December 2018. Coronary artery occlusion was assessed from angiograms using the Gensini score. Patients with infectious processes within 2 weeks before catheterization, hepatic dysfunction, thyroid dysfunction, cancer, and chronic kidney disease were excluded from the study. This study had received ethical clearance (No.06/EC/KERS/2019) from the local ethics committee. Informed consents were obtained and details which disclose patients' identity were omitted.

### Risk factor data collection

Clinical findings, 12-lead electrocardiogram, and echocardiographic examination were performed based on the American Society of Echocardiography guidelines [11]. The standard laboratory was performed to measure fasting blood glucose (FBG), total cholesterol, and renal function tests from the blood samples [12].

CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF score consists of congestive cardiac failure (C), hypertension (H), age >75 years (A), diabetes mellitus (D), stroke (S), vascular diseases (V), age 65–74 years (A), sex category (Sc), hyperlipidemia (H), smoking (S), and family history of cardiovascular disease (F) were obtained by medical record thorough examination. Congestive cardiac failure (C) score was given if left ventricular ejection fraction was reduced (<45%) from echocardiography examination. Hypertension (H) was defined as systolic blood pressure >140 mmHg or diastolic <90 mmHg for repeated measurement, or when the patient was taking antihypertensive medications. Diabetes mellitus (D) Type 2 was defined FBG >126 mg/dl, previous diabetes diagnosis, or when the patient was taking anti-diabetic medications. Stroke (S) was defined as the history or current diagnosis of stroke or TIA which was given by the patients. Vascular disease (V) was defined from the existence of a pathologic condition which causes stenosis of at least 50% in the

non-coronary artery. Hyperlipidemia (H) defined as a cholesterol level of more than 200 mg/dL based on the National Cholesterol Education Program or when the patient is consuming of lipid-lowering medications. Cigarette smoking (S) was defined as the habit of smoking of more than five cigarettes per-day without a quit attempt for a minimum of 1 year. Family history of cardiovascular disease (F) was defined as the presence of cardiovascular disease or sudden cardiac-related death of the first degree-relative.

### CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF scoring

CHA<sub>2</sub>DS<sub>2</sub> score was calculated by adding 1 point for the presence of chronic heart failure, age >75 years, DM and hypertension by assigning 2 points for the history of stroke or TIA. In the CHA<sub>2</sub>DS<sub>2</sub>-VASc score, age 65–74 was assigned for 1 point (A) and age >75 years (A<sub>2</sub>) was assigned for 2 points. The CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF score put 1 point for the finding of hyperlipidemia (h), smoking (S), and family history of the cardiac disease (F).

### Coronary angiography and Gensini scoring

Judkins technique 4 with 5-F catheters was used to perform cannulation of coronary arteries. Kodak 35-mm cinefilm was used to record the images at 30 frames/s. Computer-assisted coronary angiography analysis system was used to detect coronary stenosis (Mipron 1; Kontron, Tokyo, Japan). One minute after the injection of ISDN (2.5 mg/5 mL for 20 s) through the Judkins catheter, several projections were taken to observe the coronary angiography. Coronary atherosclerosis severity was measured using the Gensini scoring method, as described previously [12].

Calculation of the Gensini score was done for each patient through the severity score assignment based on coronary occlusion. Narrowing between 1 and 25% will be scored 1, 26–50% will be scored 2, 51–75% will be scored 3, 75–90% will be scored 8, 91–99% will be scored 16, and 100% will be scored 32. The score is then multiplied based on the location and importance of the artery. We multiply by factor 5 for left main coronary artery occlusion, 2.5 for both proximal circumflex artery and proximal left anterior descending artery, 1.5 for a mid-left anterior descending artery, and 1 mid or distal circumflex artery, for distal left anterior descending artery and the right coronary artery. The multiplication factor for any other branch is 0.5 [3].

### Statistical analyses

Data analyses were performed using SPSS Statistics 25.0 and MedCalc 18.2.1. Continuous variables, presented as mean ± standard deviation (SD), were compared using ANOVA test. Correlation between

parametric variables was obtained using Spearman's Rho followed by logistic regression. Specificity and sensitivity were obtained from the receiver operating characteristic (ROC) curve and cutoff point analysis. Area under the curve (AUC) comparison was done using the pairwise comparison method as described previously [13].

## Results

### Clinical characteristics of the patients

The total of 210 patients was involved in this study. Table/Figure 1 shows the characteristics of the participant, which grouped based on the CAD severity. Of the 210 patients, 70 patients had normal angiogram (Gensini score = 0, 33.3%), 48 patient had mild CAD (Gensini score = 1–19, 22.9%), and 92 patients had obstructive/severe CAD (Gensini score >20, 43.8%). The comparison of the baseline demographics and characteristics of the three groups (normal coronary arteries, mild CAD, and severe CAD) is presented in Table 1.

From Table 1, significant differences between severe CAD and normal angiography groups were

observed on the age, FBG, ureum, and creatinine which are the CAD risk factors. CHADS<sub>2</sub>, CHA<sub>2</sub>DS<sub>2</sub>-VASc, and CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF score also significantly higher on the patient with severe CAD compared to the patient with normal angiography.

### Correlations between multiple variables with CAD severity

The correlation test was used to identify the factors associated with the severity of CAD. Table 2 shows the results of Spearman's correlations between Gensini score and multiple independent variables in the in subjects. Spearman's correlation analysis showed that the highest correlation was identified on the CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF score with Gensini score, which showed a moderate to strong correlation ( $r = 0.612$ ,  $p \leq 0.001$ ).

### Logistic linear regression analysis of the variables to predict severe CAD

Univariate and multivariate logistic linear regression analysis was done on various variables in predicting the outcome (severe CAD) as presented in Tables 3 and 4. The analysis from Tables 3 and 4 showed that CHADS<sub>2</sub>, CHA<sub>2</sub>DS<sub>2</sub>-VASc, and CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF were significant predictors for severe CAD.

### Specificity and sensitivity test using ROC curves

From the ROC curves in Figure 1, it is suggested that CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF score has higher AUC compared to CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc score. Optimum cutoff point analysis showed that the CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF score  $\geq 2.5$  provided the highest predictive value for severe CAD (sensitivity = 81.4% and specificity = 68.1%). Pairwise comparison from Table 5 showed that the CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF score was found to be the best scoring scheme to predict severe CAD compared to CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc score.




Figure 1: Receiver operating characteristic curve of CHADS<sub>2</sub>, CHA<sub>2</sub>DS<sub>2</sub>-VASc, and CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF score to predict severe CAD. AUC: Area under the curve; CI: Confidence interval

Table 1: Characteristics of the patients based on CAD severity

Variables*	CAD severity			p-value
	Normal angiogram (n=70)	Mild CAD (n=48)	Severe CAD (n=92)	
Age (years)	50.97 ± 8.95 <sup>ab</sup>	53.87 ± 10.90 <sup>a</sup>	54.65 ± 9.13 <sup>a</sup>	$\leq 0.001$
SBP (mmHg)	131.81 ± 26.17	123.00 ± 16.67	130.90 ± 23.05	0.691
DBP (mmHg)	72.81 ± 10.86	76.53 ± 9.12	77.58 ± 9.23	0.463
Weight (kg)	69.48 ± 12.43	65.27 ± 7.70	70.03 ± 9.88	0.369
Height (m)	164.06 ± 8.59	164.33 ± 3.90	165.45 ± 5.79	0.208
BMI (kg/m <sup>2</sup> )	25.67 ± 3.26	24.22 ± 3.28	25.55 ± 3.15	0.341
Hb (g/dL)	14.01 ± 1.11	13.63 ± 1.73	14.60 ± 3.75	0.474
WBC (cells/ $\mu$ L)	7434.2 ± 1725.5	6746.0 ± 1624.1	7350.1 ± 2108.5	0.292
HCT (%)	41.63 ± 3.64	41.20 ± 4.69	42.46 ± 4.36	0.897
Platelet ( $\times 10^3$ cells/ $\mu$ L)	273.00 ± 78.55	271.66 ± 47.73	258.12 ± 52.97	0.268
PT (s)	13.31 ± 1.28	13.56 ± 2.67	13.56 ± 3.46	0.301
APTT (s)	32.56 ± 3.23	31.33 ± 6.19	33.39 ± 5.27	0.097
FBG (mg/dL)	108.06 ± 37.97 <sup>c</sup>	114.13 ± 32.82	112.45 ± 34.39 <sup>a</sup>	0.032
Ureum (mg/dL)	12.45 ± 3.15 <sup>bc</sup>	16.81 ± 5.20 <sup>a</sup>	16.45 ± 7.70 <sup>a</sup>	0.005
Creatinine (mg/dL)	1.00 ± 0.31 <sup>bc</sup>	1.27 ± 0.25 <sup>a</sup>	1.16 ± 0.26 <sup>a</sup>	0.005
Ejection fraction (%)	57.65 ± 18.31	64.73 ± 5.96	52.15 ± 16.85	0.474
CHADS <sub>2</sub> Score	0.68 ± 0.66 <sup>bc</sup>	0.60 ± 0.99 <sup>a</sup>	1.08 ± 0.94 <sup>a</sup>	$\leq 0.001$
CHA <sub>2</sub> DS <sub>2</sub> -VASc Score	1.32 ± 0.83 <sup>bc</sup>	1.47 ± 1.05 <sup>a</sup>	1.95 ± 1.04 <sup>a</sup>	$\leq 0.001$
CHA <sub>2</sub> DS <sub>2</sub> -VASc-HSF Score	2.06 ± 0.77 <sup>bc</sup>	2.33 ± 1.23 <sup>a</sup>	3.43 ± 1.20 <sup>a</sup>	$\leq 0.001$

SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BMI: Body mass index, Hb: Hemoglobin; WBC: White blood cells; HCT: Hematocrit; PT: Prothrombin time; APTT: Activated partial thromboplastin time; FBG: Fasting blood glucose; SD: Standard deviation. Values are presented as a mean±SD; different annotation showed a significant difference ( $p < 0.05$ ) for the post hoc LSD test to normal angiogram (a), mild CAD (b) and severe CAD (c).

## Discussion

The major findings of this research were: (1) CHA<sub>2</sub>DS<sub>2</sub>-VAsc-HSF score was significantly increased both mild and severe CAD patients, (2) the CHADS<sub>2</sub>,

**Table 2: Spearman's correlations between various independent variables with CAD Gensini score**

Variables*	Correlation coefficient (r)
Age (years)	0.276**
FBG (mg/dL)	0.180*
Ureum (mg/dL)	0.232**
Creatinine (mg/dL)	0.204**
WBC	0.236**
Ejection fraction (%)	-0.215**
CHA <sub>2</sub> DS <sub>2</sub>	0.315**
CHA <sub>2</sub> DS <sub>2</sub> -VAsc	0.395**
CHA <sub>2</sub> DS <sub>2</sub> -VAsc-HSF	0.612**

\*Significant correlation at p<0.05, \*\*Significant correlation at p<0.01. FBG: Fasting blood glucose; WBC: White blood cells.

CHA<sub>2</sub>DS<sub>2</sub>-VAsc, and CHA<sub>2</sub>DS<sub>2</sub>-VAsc-HSF scores have positive and significant correlation with CAD severity measured by Gensini score, (3) CHADS<sub>2</sub>, CHA<sub>2</sub>DS<sub>2</sub>-VAsc,

**Table 3: Univariate regression analysis for the predictors of severe CAD**

Variables	Odds ratio	95% CI	p-value
Age (years)	1.036	1.007-1.066	0.013
SBP (mmHg)	1.003	0.992-1.015	0.595
DBP (mmHg)	1.015	0.990-1.042	0.242
BMI (kg/m <sup>2</sup> )	1.016	0.933-1.106	0.721
Hb (g/dL)	1.072	0.861-1.335	0.551
WBC (cells/μL)	1.000	1.000-1.000	0.676
HCT (%)	0.995	0.899-1.102	0.929
Platelet (× 10 <sup>3</sup> cells/μL)	1.000	1.000-1.000	0.515
FBG (mg/dL)	1.009	1.001-1.017	0.024
Ureum (mg/dL)	1.103	1.045-1.164	≤0.001
Creatinine (mg/dL)	5.000	1.756-14.233	≤0.001
Ejection fraction (%)	0.390	0.059-2.563	0.474
CHA <sub>2</sub> DS <sub>2</sub> score	1.834	1.304-2.580	≤0.001
CHA <sub>2</sub> DS <sub>2</sub> -VAsc score	1.962	1.455-2.644	≤0.001
CHA <sub>2</sub> DS <sub>2</sub> -VAsc-HSF score	2.716	1.996-3.696	≤0.001

SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BMI: Body mass index, Hb: Hemoglobin; WBC: White blood cells; HCT: Hematocrit; PT: Prothrombin time; APTT: Activated partial thromboplastin time; FBG: Fasting blood glucose.

and CHA<sub>2</sub>DS<sub>2</sub>-VAsc-HSF are significant predictors for severe CAD, the highest odds ratio was found on the CHA<sub>2</sub>DS<sub>2</sub>-VAsc-HSF score, and (4) CHA<sub>2</sub>DS<sub>2</sub>-VAsc-HSF was the best score to predict severe CAD with the cutoff point of ≥2.5.

**Table 4: Multivariate regression analysis for the predictors of severe CAD**

Variables	Odds ratio	95% CI	p-value
<b>With CHADS<sub>2</sub> score</b>			
Age (years)	1.017	0.985-1.049	0.296
FBG (mg/dL)	1.002	0.994-1.011	0.588
Ureum (mg/dL)	1.067	1.008-1.130	0.026
Creatinine (mg/dL)	2.828	0.893-8.960	0.077
CHADS <sub>2</sub> Score	1.572	1.009-2.345	0.046
<b>With CHA<sub>2</sub>DS<sub>2</sub>-VAsc score</b>			
Age (years)	1.008	0.976-1.042	0.613
FBG (mg/dL)	1.002	0.994-1.010	0.601
Ureum (mg/dL)	1.065	1.008-1.129	0.032
Creatinine (mg/dL)	2.323	0.731-7.380	0.153
CHA <sub>2</sub> DS <sub>2</sub> -VAsc score	1.569	1.098-2.240	0.013
<b>With CHA<sub>2</sub>DS<sub>2</sub>-VAsc-HSF score</b>			
Age (years)	0.997	0.962-1.033	0.671
FBG (mg/dL)	0.997	0.989-1.006	0.516
Ureum (mg/dL)	1.065	0.998-1.137	0.056
Creatinine (mg/dL)	1.511	0.421-5.419	0.527
CHA <sub>2</sub> DS <sub>2</sub> -VAsc-HSF Score	2.540	1.794-3.595	0.002

FBG: Fasting blood glucose; CI: Confidence interval.

**Table 5: Pairwise comparison between receiver operating characteristic curves**

Variables	Differences between areas	SE	95% CI	Z-Statistic	p-value
CHADS <sub>2</sub> and CHA <sub>2</sub> DS <sub>2</sub> -VAsc	0.0496	0.0227	0.0052-0.941	2.190	0.028
CHADS <sub>2</sub> and CHA <sub>2</sub> DS <sub>2</sub> -VAsc-HSF	0.154	0.0320	0.0914-0.217	4.819	≤0.001
CHA <sub>2</sub> DS <sub>2</sub> -VAsc and CHA <sub>2</sub> DS <sub>2</sub> -VAsc-HSF	0.105	0.0255	0.0546-0.154	4.105	≤0.001

SE: Standard error; CI: Confidence interval.

The severe CAD may be fatal if remained undiagnosed and developed further into coronary total occlusion, which caused myocardial infarction. Hence, early detection of severe CAD is extremely important to prevent the mortality and morbidity of the patients [3]. Coronary angiography is the gold standard to diagnose the severity of stable CAD. However, early coronary angiography screening is lacking in developing countries [14]. Hence, clinicians need reliable, simple, objective, and quantitative tools to identify these risk stratifications to refer the patient for early screening, modify the risk factor, and provide early treatment [15]. Several scoring systems which involve major risk factors such as European SCORE and Framingham risk score (FRS) have been developed to assess the risk of CAD [16]. FRS is the most widely used score, which estimates the 10-year risk of developing CAD risk. However, this score cannot assess the severity of CAD. Furthermore, FRS also overestimates cardiovascular mortality rates in a low-risk population and underestimates it at the high-risk populations [17], [18]. Due to its multiplicity and complexity, FRS, SCORE, and other scoring systems are considered to be unpractical for daily use for primary care physician [19], [20]. Hence, alternatives scoring such as that CHADS<sub>2</sub>, CHA<sub>2</sub>DS<sub>2</sub>-VAsc, and CHA<sub>2</sub>DS<sub>2</sub>-VAsc-HSF may offer a better alternative, which is easily be applied by the physician without any additional cost.

This study showed that CHADS<sub>2</sub>, CHA<sub>2</sub>DS<sub>2</sub>-VAsc, and CHA<sub>2</sub>DS<sub>2</sub>-VAsc-HSF are having a positive and significant correlation with CAD severity measured by Gensini score. The highest correlation was found on the CHA<sub>2</sub>DS<sub>2</sub>-VAsc-HSF score. This was in accordance with the previous research that showed both CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VAsc score are significantly correlated with the Gensini score with almost similar r-value (r = 0.383, p < 0.001; r = 0.300, p = 0.001) [15]. When CHA<sub>2</sub>DS<sub>2</sub>-VAsc score is modified by adding hyperlipidemia (H) and smoking (S), a stronger and significant correlation was found between CHA<sub>2</sub>DS<sub>2</sub>-VAsc-HS score and Gensini score (r = 0.813, p < 0.001) [21]. Similar to this research, CHA<sub>2</sub>DS<sub>2</sub>-VAsc-HSF also has a stronger and significant correlation with the severity of CAD measured by syntax score in NSTEMI patients compared to CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VAsc [22]. This suggested that CHA<sub>2</sub>DS<sub>2</sub>-VAsc-HSF score has a superior association with CAD severity compared to CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VAsc score.

We investigated whether the CHADS<sub>2</sub>-VAsc-HSF scores could aid clinicians to predict the patient who has higher odds of severe CAD, which need immediate diagnosis and treatments. This research showed that CHA<sub>2</sub>DS<sub>2</sub>-VAsc-HSF has the highest odd

ratio to predict the severe CAD compared to CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc. Previously, the CHADS<sub>2</sub> score, as one of the rapid and very practical scores for risk stratification for thromboembolism, has also shown able to predict CAD in ischemic stroke patients [23]. The development of CHADS<sub>2</sub> into CHA<sub>2</sub>DS<sub>2</sub>-VASc score also has been shown to have better predictive power for long-term mortality for patients with severe CAD [24]. This suggested that the improvement of CHA<sub>2</sub>DS<sub>2</sub>-VASc into CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF may provide a better prediction for the odds of having severe CAD.

The CHADS<sub>2</sub> score is considered as one of the rapid, wide range, and very practical for risk stratification for thromboembolism, which was also developed to predict CAD in ischemic stroke patients [23]. CHA<sub>2</sub>DS<sub>2</sub>-VASc is the development of the CHADS<sub>2</sub> score, which showed better predictive power for long-term mortality for patients with CAD [24]. When compared with TIMI, GRACE score, CHA<sub>2</sub>DS<sub>2</sub>-VASc showed that the capability to predict severe CAD measured by syntax score [25]. Modification of CHA<sub>2</sub>DS<sub>2</sub>-VASc into CHA<sub>2</sub>DS<sub>2</sub>-VASc-HS score also has been shown to improve its predictive value for severe CAD compared to both CHADS<sub>2</sub> into CHA<sub>2</sub>DS<sub>2</sub>-VASc with the sensitivity of 85.2% and specificity of 57.5% at the cutoff value of >2 [13]. In this research, modification of CHA<sub>2</sub>DS<sub>2</sub>-VASc into CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF score also showed a higher AUC area compared to both CHADS<sub>2</sub> into CHA<sub>2</sub>DS<sub>2</sub>-VASc score with the sensitivity of 81.4% and specificity of 68.1% at the cutoff value of >2.5. CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF also shown to be the best scoring scheme for severe CAD prediction compared to CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc score. This suggests that CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF score is a better scoring method which easily used by the physician to screen the patient with angina, which may require referral for coronary angiography and early treatment.

However, this study may yet to be generalized since it only involved a single-center as the source of data. This study also used consecutive samplings from all patients who were admitted for diagnostic coronary angiography. Hence, selection bias might occur. In the future, it is suggested to involve more cardiac center and stratify the sample based on several factors such as race and social status to ensure the validity of the score among various demographic characteristics.

## Conclusions

The CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF score can predict the severe CAD with superior validity compared to CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc score. Suggesting that CHA<sub>2</sub>DS<sub>2</sub>-VASc-HSF score may be recommended for primary care physicians to easily predict severe CAD and refer them earlier without additional costs.

## Authors' Contributions

Conceptualization, A. and M.J.A.; Methodology, R.L.; Software, M.J.A. and R.L.; Validation, A. and B.J.; Formal analysis, M.J.A. and R.L.; Investigation, I.G.P.G.S., M.J.A., and K.A.S.; Resources, A. and B.J.; Data curation, I.G.P.G.S. and K.A.S.; writing—original draft preparation, I.G.P.G.S. and K.A.S.; writing—review and editing, A. and M.J.A.; visualization, R.L.; supervision, A. and B.J.; project administration, R.L.

## References

- Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, *et al.* Heart disease and stroke statistics-2008 update: A report from the American heart association statistics committee and stroke statistics subcommittee. *Circulation*. 2008;117(4):e25-146. <https://doi.org/10.1161/circulationaha.107.187998> PMID:18086926
- Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, *et al.* Heart disease and stroke statistics-2018 update: A report from the American heart association. *Circulation*. 2018;137(12):e67-492. <https://doi.org/10.1161/cir.0000000000000573> PMID:29386200
- Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. *Lancet*. 1999;353(9147):89-92. [https://doi.org/10.1016/S0140-6736\(98\)10279-9](https://doi.org/10.1016/S0140-6736(98)10279-9) PMID:10023892
- Ministry of Health Indonesia. Sample Registration System 2014. Indonesia: NIHRD Library Cataloguing in Publication Data; 2015. Available from: <https://www.litbang.kemkes.go.id/wp-content/uploads/2017/10/final-report-srs-2014.pdf>. [Last accessed on 2019 Mar20].
- Kočka V. The coronary angiography-an old-timer in great shape. *Cor et Vasa*. 2015;57(6):e419-24. <https://doi.org/10.1016/j.crvasa.2015.09.007>
- Modesti PA, Agostoni P, Agyemang C, Basu S, Benetos A, Cappuccio FP, *et al.* Cardiovascular risk assessment in low-resource settings: A consensus document of the European society of hypertension working group on hypertension and cardiovascular risk in low resource settings. *J Hypertens*. 2014;32(5):951-60. <https://doi.org/10.1097/hjh.0000000000000125> PMID:24577410
- January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr., *et al.* 2019 focused update on atrial fibrillation AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American college of cardiology/American Heart Association task force on clinical practice guidelines and the heart rhythm society. *J Am Coll Cardiol* 2019;140:e125-e51. <https://doi.org/10.1161/cir.0000000000000665>
- Henriksson KM, Farahmand B, Johansson S, Asberg S, Terént A, Edvardsson N. Survival after stroke—the impact of CHADS<sub>2</sub> score and atrial fibrillation. *Int J Cardiol*. 2010;141(1):18-23. <https://doi.org/10.1016/j.ijcard.2008.11.122> PMID:19144430
- Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, *et al.* Ventricular dysfunction and the risk of stroke after myocardial infarction. *N Engl J Med*. 1997;336(4):251-7.



- <https://doi.org/10.1056/nejm199701233360403>  
PMid:8995087
10. Yarmohammadi H, Varr BC, Puwanant S, Lieber E, Williams SJ, Klostermann T, *et al.* Role of CHADS2 score in evaluation of thromboembolic risk and mortality in patients with atrial fibrillation undergoing direct current cardioversion (from the ACUTE trial substudy). *Am J Cardiol.* 2012;110(2):222-26. <https://doi.org/10.1016/j.amjcard.2012.03.017>  
PMid:22503581
  11. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, *et al.* Recommendations for chamber quantification: A report from the American society of echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European association of echocardiography, a branch of the European Society of cardiology. *J Am Soc Echocardiogr.* 2005;18(12):1440-63. <https://doi.org/10.1016/j.echo.2005.10.005>  
PMid:16376782
  12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem.* 1972;18(6):499-502. <https://doi.org/10.1093/clinchem/18.6.499>  
PMid:4337382
  13. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. *Biometrics.* 1988;44(3):837-45. <https://doi.org/10.2307/2531595>  
PMid:3203132
  14. Zhao Y, Shaista M, Nathan D. Evidence for coronary artery calcification screening in the early detection of coronary artery disease and implications of screening in developing countries. *Glob Heart.* 2014;9(4):399-407. <https://doi.org/10.1016/j.gheart.2014.10.005>  
PMid:25592793
  15. Cetin M, Cakici M, Zencir C, Tasolar H, Baysal E, Balli M, *et al.* Prediction of coronary artery disease severity using CHADS2 and CHA2DS2-VASc scores and a newly defined CHA2DS2-VASc-HS score. *Am J Cardiol.* 2014;113(6):950-6. <https://doi.org/10.1016/j.amjcard.2013.11.056>  
PMid:24444782
  16. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. *Am Heart J.* 1991;121(1):293-8.  
PMid:1985385
  17. Menotti A, Puddu PE, Lanti M. Comparison of the framingham risk function-based coronary chart with risk function from an Italian population study. *Eur Heart J.* 2000;21(5):365-70. <https://doi.org/10.1053/euhj.1999.1864>  
PMid:10666350
  18. Onat A, Can G, Hergenç G, Küçükduymaz Z, Uğur M, Yüksel H. High absolute coronary disease risk among Turks: Involvement of risk factors additional to conventional ones. *Cardiology.* 2010;115(4):297-306. <https://doi.org/10.1159/000312009>  
PMid:20395681
  19. Siontis GC, Tzoulaki I, Siontis KC, Ioannidis JP. Comparisons of established risk prediction models for cardiovascular disease: Systematic review. *BMJ.* 2012;344:e3318. <https://doi.org/10.1136/bmj.e3318>  
PMid:22628003
  20. D'Agostino RB Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, *et al.* General cardiovascular risk profile for use in primary care: The framingham heart study. *Circulation.* 2008;117(6):743-53. <https://doi.org/10.1161/circulationaha.107.699579>  
PMid:18212285
  21. Naik G, Sekhar S, Prabhu M, Singh G, Vijay A, Subrahmanian M, *et al.* Comparison of CHA2DS2-VASc-HS score and gensini score to predict severity of coronary artery disease. *J Clin Diagn Res.* 2018;12(7):IC01-4. <https://doi.org/10.7860/jcdr/2018/28509.11802>
  22. Al-shorbagy AN, Al-Cekelly MM, Dwedara AA, Soliman MM. The predictive value of newly defined CHA2DS2-VASc-HSF score for severity of coronary artery disease in non ST segment elevation myocardial infarction. *Zagazig Univ Med J.* 2018;24(4):289-96. <https://doi.org/10.21608/zumj.2018.13209>
  23. Poci D, Hartford M, Karlsson T, Herlitz J, Edvardsson N, Caidahl K. Role of the CHADS2 score in acute coronary syndromes: Risk of subsequent death or stroke in patients with and without atrial fibrillation. *Chest.* 2012;141(6):1431-40. <https://doi.org/10.1378/chest.11-0435>  
PMid:22016485
  24. Kim KH, Kim W, Hwang SH, Kang WY, Cho SC, Kim W, *et al.* The CHA2DS2VASc score can be used to stratify the prognosis of acute myocardial infarction patients irrespective of presence of atrial fibrillation. *J Cardiol.* 2015;65(2):121-7. <https://doi.org/10.1016/j.jjcc.2014.04.011>  
PMid:24972564
  25. Bozbay M, Uyarel H, Cicek G, Oz A, Keskin M, Murat A, *et al.* CHA2DS2-VASc score predicts in-hospital and long-term clinical outcomes in patients with st-segment elevation myocardial infarction who were undergoing primary percutaneous coronary intervention. *Clin Appl Thromb Hemost.* 2017;23(2):132-8. <https://doi.org/10.1177/1076029616646874>  
PMid:27170782